Related Experiment Video

Updated: Jul 11, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Hemostasis and global fibrinolytic capacity in chronic liver disease

Sirin Aytac1, Cansel Turkay, Nuket Bavbek

  • 1Department of Gastroenterology, Guven Hospital, Ankara, Turkey.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|September 25, 2007
PubMed

Insights

Patients with chronic liver disease exhibit accelerated fibrinolysis, indicated by elevated global fibrinolytic capacity (GFC). This hyperfibrinolysis may contribute to bleeding risks in these individuals.

Area of Science:

  • Hematology
  • Hepatology
  • Clinical Chemistry

Background:

  • Liver disease is associated with abnormal fibrinolysis, often assessed by nonspecific tests.
  • Existing methods may not fully capture the global fibrinolytic capacity (GFC) involving both intrinsic and extrinsic pathways.

Purpose of the Study:

  • To evaluate the global fibrinolytic capacity (GFC) in patients with chronic liver disease using a novel method.
  • To compare GFC between patients with chronic liver disease and healthy controls.

Main Methods:

  • A semiquantitative macrolatex agglutination assay was used to measure GFC.
  • Forty patients with chronic liver disease (hepatitis, cirrhosis, hepatocellular carcinoma) and 17 healthy controls were studied.

Main Results:

  • Global fibrinolytic capacity (GFC) was significantly higher in patients with chronic liver disease compared to controls (P < 0.05).
  • No significant differences in GFC were observed among the different chronic liver disease patient groups.
  • GFC showed a positive correlation with prothrombin time and activated partial thromboplastin time, and a negative correlation with thrombocyte count.

Conclusions:

  • Patients with chronic liver disease demonstrate hyperfibrinolysis, as evidenced by increased GFC.
  • The GFC measurement provides insight into the net fibrinolytic state in chronic liver disease, potentially explaining bleeding tendencies.

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...